Murali Vridhachalam

The convergence of cloud, data and AI is revolutionizing the pharmaceutical industry, creating a powerful ecosystem that drives innovation at scale across the entire value chain. At Gilead, teams harness these technologies on a unified cloud, data, & AI platform, accelerating business processes in pre-clinical and clinical stage, enabling smarter manufacturing and commercial processes, and deliver AI initiatives by reusing data products. Gilead will discuss how they have leveraged AWS, Databricks, and Data Mesh to manage vast amounts of heterogeneous data. Also, showcase use cases of traditional AI/ML, and Generative AI, and a Marketplace approach to drive adoption of AI Agents, demonstrating how this cloud-based, AI-powered platform is transforming the entire value chain. Gilead will also discuss how they are exploring the future of pharmaceutical innovation through Agentic AI, where the synergy of cloud, data and AI is unlocking new possibilities for a healthier world. In the second part, Muddu Sudhakar, Founder and Investor, will discuss how organizations can build and buy solutions for AI, Agents with Data Platforms. AWS and Databricks provide industry-leading platforms to…

Generative AI is rapidly gaining traction across all industries and modern cloud-based ecosystems, including pharmaceutical life sciences. However, there are a number of unique benefits and risks, especially given the highly regulated environment and potential for long-standing impact to millions of lives.

To accelerate the development of therapies for life-threatening diseases, Gilead Sciences, a global biopharmaceutical company, needs fast, agile, and secure access to critical data. In this session, learn how Gilead collaborated with AWS as their strategic cloud provider to migrate critical applications and improve their ability to perform advanced data analysis through the establishment of a...